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The mechanisms of tumor metastasis to the sentinel lymph nodes are poorly understood. 
Vascular endothelial growth factor (VEGF)-A plays a principle role in tumor progression 
and angiogenesis; however, its role in tumor-associated lymphangiogenesis and lymphatic 
metastasis has remained unclear. We created transgenic mice that overexpress VEGF-A 
and green fluorescent protein specifically in the skin, and subjected them to a standard 
chemically-induced skin carcinogenesis regimen. We found that VEGF-A not only strongly 
promotes multistep skin carcinogenesis, but also induces active proliferation of VEGF 
receptor-2–expressing tumor-associated lymphatic vessels as well as tumor metastasis to 
the sentinel and distant lymph nodes. The lymphangiogenic activity of VEGF-A–expressing 
tumor cells was maintained within metastasis-containing lymph nodes. The most surprising 
finding of our study was that even before metastasizing, VEGF-A–overexpressing primary 
tumors induced sentinel lymph node lymphangiogenesis. This suggests that primary tumors 
might begin preparing their future metastatic site by producing lymphangiogenic factors 
that mediate their efficient transport to sentinel lymph nodes. This newly identified 
mechanism of inducing lymph node lymphangiogenesis likely contributes to tumor 
metastasis, and therefore, represents a new therapeutic target for advanced cancer 
and/or for the prevention of metastasis.
 
Angiogenesis, the growth of new blood vessels
from preexisting vessels, is essential for tumor
growth (1). Vascular endothelial growth factor
(VEGF)-A has been identified as the predomi-
nant tumor angiogenesis factor in the majority
of human and experimental murine cancers
(2), acting via VEGF receptor (VEGFR)-1 and
VEGFR-2. Recent studies in mouse tumor
models, however, have suggested that some
types of malignant tumors also induce the for-
mation of lymphatic vessels (lymphangiogenesis),
and that this process promotes tumor spread to
regional lymph nodes (3–5). Moreover, tumor
lymphangiogenesis has been identified as a
novel prognostic factor for determining the
risk for human cutaneous melanomas to be-
come metastatic (6).
In contrast to the detailed characteriza-
tion of the molecular mechanisms that control
(blood vascular) angiogenesis, the mechanisms
underlying the pathologic growth and function
of the lymphatic vascular system have remained
poorly understood. Thus far, VEGF-C and
VEGF-D are the only known lymphangiogenesis
factors—acting predominantly through activa-
tion of VEGFR-3—which is expressed by
lymphatic endothelium in vivo and in vitro (7).
Several studies in animal tumor models have
provided direct experimental evidence that
increased levels of VEGF-C or VEGF-D
promote tumor lymphangiogenesis and tumor
spread via the lymphatic vessels to regional
lymph nodes. Furthermore, these effects can be
suppressed by blocking VEGFR-3 signaling
(3–5, 8–10). Other factors, however, are likely
to be involved in mediating tumor lymphangio-
genesis and metastasis to the lymph nodes (11).
Generally, VEGF-A has been considered
to only promote (blood vascular) angiogenesis;
however, recent work from several laborato-
ries revealed that VEGF-A promotes human
lymphatic endothelial cell proliferation and mi-
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gration in vitro (12–15), and that lymphatic endothelium
expresses VEGFR-2 in situ and in vitro (12, 13, 16–18).
Moreover, intradermal injection of mice with an adenoviral
vector engineered to express mouse VEGF-A, but not with
adenoviral human VEGF-A (18), resulted in the production
of enlarged, proliferating lymphatic vessels (16). Our recent
work has shown that chronic transgenic delivery of VEGF-A
to mouse skin promoted lymphangiogenesis associated with
chronic skin inflammation (19) and with cutaneous tissue
repair (13).
To investigate whether VEGF-A also might be involved
in mediating tumor lymphangiogenesis and metastasis to the
lymph node, we generated a new transgenic mouse model to
target expression of GFP to normal and malignant epidermal
keratinocytes. GFP expression was controlled by a keratin 14
(K14) promoter-driven transgene cassette. This model en-
ables the sensitive detection and quantification of lymph
node metastasis during experimental, multi-step skin car-
cinogenesis. We then crossed these mice with our previously
established K14/VEGF-A transgenic mice (20, 21), and
subjected the offspring, which produce fluorescent kerati-
nocytes in the skin that also overexpress VEGF-A, to a
chemically induced, multi-step skin carcinogenesis regimen
(22, 23).
We found that targeted overexpression of VEGF-A po-
tently induced tumor lymphangiogenesis in cutaneous squa-
mous cell carcinoma (SCC) and promoted tumor metastasis to
sentinel lymph nodes. Importantly, VEGF-A–expressing tu-
mor cells maintained their lymphangiogenic activity after me-
tastasis to lymph nodes. Surprisingly, VEGF-A–overexpressing
cutaneous SCC induced lymphangiogenesis in sentinel lymph
nodes, even before the tumors had metastasized to these
tissues. Together, these results identify VEGF-A as a novel tu-
mor lymphangiogenesis factor. They also indicate that VEGF-
A–induced lymph node lymphangiogenesis promotes metasta-
sis, and therefore, is an important target for the treatment of
advanced cancer and the prevention of metastasis.
 
RESULTS
Transgenic expression of GFP in the skin enables detection 
and quantification of SCC metastasis to lymph nodes
 
To facilitate detection and quantification of skin cancer me-
tastases, we created a transgenic mouse model to selectively
express GFP in epidermal keratinocytes, using a K14 pro-
moter cassette (Fig. 1 A). Three transgenic founder lines ex-
pressed high levels of GFP in the skin; targeted expression of
the K14/GFP transgene in the basal epidermal keratinocyte
layer and in outer root sheath keratinocytes of hair follicles
was confirmed by fluorescence microscopy (Fig. 1 B). In-
duction of epidermal hyperplasia by topical application of
PMA to the ear skin of transgenic mice resulted in strong
GFP expression throughout the hyperplastic epidermis at 1
and 4 d afterward (Fig. 1 C, D).
To investigate whether GFP expression also was main-
tained during the successive stages of multi-step skin car-
cinogenesis and metastasis, the K14/GFP transgenic line that
expressed the highest level of GFP was subjected to a stan-
dard 7,12-dimethylbenzanthracene (DMBA)/PMA chemical
skin carcinogenesis regimen. This involved a single dose of
DMBA to initiate tumor formation, followed by 20 weekly
applications of the tumor promoter PMA. High levels of
GFP expression were detected in all of the cells of early be-
nign papillomas that already displayed marked tumor angio-
Figure 1. K14/GFP transgenic mice provide a reliable new model 
for the detection of skin cancer metastases. (A) Schematic representa-
tion of the K14-GFP transgenic construct. A 720-bp enhanced GFP (EGFP) 
cDNA fragment was ligated to the BamHI restriction site of the keratin 14 
promoter cassette. (B) Targeted expression of the K14/GFP transgene in 
the basal epidermal keratinocyte layer and in outer root sheath kerati-
nocytes of hair follicles was confirmed by fluorescence microscopy (green). 
(C and D) Induction of epidermal hyperplasia by topical application of 
PMA resulted in strong GFP expression throughout the epidermis. Nuclei 
are labeled blue (Hoechst stain). (E and F) High levels of GFP expression 
(green) were maintained in tumor cells of papillomas (E) and of SCC (F) 
induced by the chemical skin carcinogenesis regimen. Immunostains for 
the panvascular marker CD31 (E; red) revealed tumor-associated angio-
genesis, whereas immunostains for the lymphatic-specific marker LYVE-1 
(F; red; arrowheads) demonstrated lymphangiogenesis in close association 
with tumor cells at the advancing tumor edge. (G and H) Metastatic tumor 
cells in sentinel lymph nodes of K14/GFP transgenic mice maintained high 
levels of GFP expression, enabling simple detection of lymph node metastasis 
by fluorescence microscopy (G, green) and quantification of GFP-positive 
and CD45-negative metastatic tumor cells (66.2% of all cells in this repre-
sentative case) by FACS analysis of single cell suspensions (H). Bars, 100 
 m (B–F), 500  m (G). 
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genesis, as detected by stains for the vascular marker CD31,
adjacent to the GFP-expressing tumor cells (Fig. 1 E). Simi-
larly, SCC cells maintained strong GFP expression, and
immunostains for the lymphatic-specific marker lymphatic
vessel endothelial hyaluronan receptor 1 (LYVE-1) demon-
strated lymphangiogenesis in close association with tumor
cells at the advancing tumor edge (Fig. 1 F). Importantly,
metastatic tumor cells in sentinel lymph nodes of K14/GFP
transgenic mice also maintained strong GFP expression, en-
abling the simple detection of metastasis to the lymph node
by fluorescence microscopy (Fig. 1 G).
We investigated whether the extent of metastasis to the
lymph node might be quantified by flow cytometry analysis of
homogenized lymph nodes. GFP-positive/CD45-negative tu-
mor cells were easily detectable and represented up to 
 
 
 
66.2%
of all sorted lymph node cells (Fig. 1 H). Together, these re-
sults established the K14/GFP transgenic model as a suitable
model for comparative studies of skin cancer metastasis.
 
Accelerated and increased skin carcinogenesis in VEGF-A 
transgenic mice
 
To investigate the effects of VEGF-A on tumor progression
and metastasis, we crossed our line of K14/GFP mice that
expressed the highest level of GFP with previously estab-
lished and characterized heterozygous K14/VEGF-A trans-
genic mice (20). This led to the establishment of K14/GFP
and K14/GFP/VEGF-A transgenic mice. These mice were
then subjected to the skin carcinogenesis regimen described
above. VEGF-A transgenic mice showed accelerated forma-
tion of skin papillomas, with an average latency period of 6
wk after the first PMA application, as compared with 12 wk
for wild-type mice (Fig. 2 A). By 7 wk, 100% of VEGF-A
transgenic mice had developed papillomas, whereas none of
the wild-type mice had developed any visible tumor at this
time point (Fig. 2 A). The number of papillomas also was in-
creased dramatically in VEGF-A transgenic mice. After 20
wk of PMA treatment, VEGF-A overexpression resulted in
the formation of more than 40 papillomas per mouse, as
compared with less than 7 papillomas that formed, on the
average, in wild-type mice (P 
 
 
 
 0.001; Fig. 2 B).
Similar, although less pronounced, effects were found
when only larger papillomas (diameter 
 
 
 
3 mm) were evalu-
ated. In VEGF-A transgenic mice, large papillomas devel-
oped 4 wk earlier than in wild-type mice (Fig. 2 C), and the
average number of large papillomas was increased by 3.4-
fold in VEGF-A transgenic mice (Fig. 2 D; P 
 
 
 
 0.001). The
average latency period for the development of malignant
SCC was 20 wk in VEGF-A transgenic mice, as compared
with 28 wk in wild-type mice (Fig. 2 E). Furthermore, all of
the VEGF-A transgenic mice had developed SCC by 28 wk
after carcinogen treatment, whereas only 50% of the wild-
type mice (Fig. 2 E) developed SCC by this time point. The
average number of SCC was increased by 3.6-fold in VEGF-A
transgenic mice (Fig. 2 F; P 
 
 
 
 0.001). No significant dif-
ferences in the ratio of malignant conversion of large papillo-
mas to SCC were found between the two genotypes (Fig. 2
G), and no papillomas or carcinomas were observed in wild-
type or VEGF-A transgenic mice treated with DMBA or
with PMA alone (data not depicted).
 
Increased tumor lymphangiogenesis and angiogenesis in 
VEGF-A transgenic mice
 
We next investigated the effects of chronic VEGF-A over-
expression on the tumor-associated formation of lymphatic
and blood vessels, which can be detected with antibodies
against LYVE-1 and CD31. We found that vascularization
Figure 2. Accelerated and increased skin carcinogenesis in VEGF-A 
transgenic mice. (A) Accelerated development of skin papillomas in 
VEGF-A transgenic mice (n   34; filled squares), as compared with wild-
type mice (n   31; open circles). Incidence is expressed as the percentage 
of mice with detectable papillomas ( 1 mm) during the 20 wk of topical 
PMA application. (B) Significant increase in frequency of papilloma forma-
tion in VEGF-A transgenic mice, expressed as the average number of pap-
illomas per mouse. P   0.01 at wk 6, P   0.001 from wk 7 to 20. (C) Accel-
erated development of large papillomas ( 3 mm) in VEGF-A transgenic 
mice. (D) Increased frequency of large papillomas in VEGF-A transgenic 
mice. P   0.01 from wk 11 to 13; P   0.001 from wk 14 to 20. (E) Increased 
incidence of SCC in VEGF-A transgenic mice. (F) Increased number of SCC 
per mouse in VEGF-A transgenic mice. P   0.01 from wk 19 to 22; P   0.001 
after 23 wk. (G) Comparable ratio of malignant conversion of large pap-
illomas into SCC in VEGF-A transgenic and wild-type mice. 
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increased in papillomas and SCC in both genotypes, com-
pared with their PMA-treated normal skin (Fig. 3 A, B);
however, tumor angiogenesis was more prominent in
VEGF-A transgenic mice (Fig. 3, D and F, and Fig. 5 B)
than in wild-type mice (Fig. 3, C and E, and Fig. 5 A).
Surprisingly, the benign papillomas that developed in
VEGF-A transgenic mice also had increased numbers of
greatly enlarged peritumoral lymphatic vessels, and peritu-
moral lymphangiogenesis was even more pronounced in
the SCCs of VEGF-A transgenic mice, compared with tu-
mors of wild-type mice (Fig. 3 C–F). Double-immunoflu-
orescence analysis of SCC for the proliferation marker
BrdU and for LYVE-1 revealed numerous proliferating
lymphatic endothelial cells in VEGF-A transgenic mice
(Fig. 3 H). Proliferating lymphatic endothelial cells were
observed only occasionally in wild-type mice (Fig. 3 G). So
VEGF-A seems to promote tumor lymphangiogenesis.
Computer-assisted morphometric analysis confirmed that
the relative area occupied by CD31-positive vessels (blood
vessels), as well as the average size of blood vessels, was in-
creased significantly (P 
 
 
 
 0.001) in the peritumoral area
of VEGF-A transgenic mice—compared with wild-type
mice—throughout the successive stages of skin carcinogene-
sis (Fig. 3 I, J). No significant difference was detected, how-
ever, in the number of blood vessels between the genotypes
(Fig. 3 K). Intratumoral blood vessels also were increased in
size and number in VEGF-A transgenic mice (P 
 
 
 
 0.001;
Fig. 3 I–K).
Figure 3. Enhanced tumor angiogenesis and lymphangiogenesis in 
VEGF-A transgenic mice. Immunofluorescence analysis with antibodies 
against CD31 (green) and LYVE-1 (red) of PMA-treated skin (A and B), early 
papillomas (C and D) and SCC (E and F) of wild-type (A,C,E) and VEGF-A 
transgenic mice (B,D,F) demonstrate highly increased vascularization of 
papillomas and SCC in both genotypes, as compared with PMA-treated 
skin. Tumor angiogenesis and lymphangiogenesis were more prominent in 
VEGF-A transgenic mice (D and F) than in wild-type mice (C and E). Note 
enlargement of blood vessels (green) and lymphatic vessels (red) in VEGF-A 
transgenic mice. (G and H) Double-immunofluorescence analysis of SCC 
for the proliferation marker BrdU (green; arrowheads) and the lymphatic 
marker LYVE-1 (red) revealed numerous proliferating lymphatic endothe-
lial cells in VEGF-A transgenic mice (H), as compared with only occasional 
proliferating lymphatic endothelial cells observed in wild-type mice (G). 
This indicates that VEGF-A promotes tumor lymphangiogenesis. Nuclei 
are labeled blue (Hoechst stain). Scale bars   100  m. (I–N) Computer-
assisted morphometric analysis of normal cutaneous and of tumor-associated 
lymphatic and blood vessels. (I) Significant increase of the relative area 
occupied by blood vessels in the peritumoral area (Peri SCC) as well as 
within SCC (Intra SCC), in VEGF-A transgenic mice (filled bars), as com-
pared with wild-type mice (open bars). (J) The average blood vessel size 
was increased significantly in the intratumoral and the peritumoral areas 
of SCC in VEGF-A transgenic mice, as compared with wild-types, whereas 
the blood vessel density only was increased in the intratumoral areas (K). 
(L) Significant increase of the relative area occupied by lymphatic vessels 
in VEGF-A transgenic mice throughout all stages of skin carcinogenesis. 
(M) Significantly increased lymphatic vessel size in the peritumoral area of 
SCC, but not in the intratumoral area of VEGF-A transgenic mice. (N) No 
significant differences were found in tumor-associated lymphatic vessel 
density between the two genotypes. Data are expressed as mean   SEM. 
*P   0.05; **P   0.01; ***P   0.001. 
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Importantly, we observed that the size of peritumoral
lymphatic vessels increased in the SCCs that formed in
VEGF-A transgenic mice, as compared with wild-type mice
(P 
 
 
 
 0.01; Fig. 3 M). This resulted in a significant increase
in the relative peritumoral area occupied by lymphatic ves-
sels (P 
 
 
 
 0.001; Fig. 3 L), whereas no significant difference
was observed in the number of lymphatic vessels (Fig. 3 N).
Similarly, the relative intratumoral area occupied by lym-
phatic vessels was increased in VEGF-A transgenic mice
(Fig. 3 L).
 
Tumor-associated lymphatic vessels of VEGF-A transgenic 
mice express VEGFR-2
 
We further characterized tumor-associated lymphangiogene-
sis in VEGF-A transgenic mice by evaluating expression lev-
els of other vessel-associated factors. In benign papillomas,
CD31-positive blood vessels frequently were found to in-
vade tumor nests, whereas LYVE-1–positive lymphatic ves-
sels remained within the peritumoral stroma (Fig. 4 A). In
contrast, lymphatic vessels frequently were found within ma-
lignant SCC (Fig. 4 B). Intratumoral LYVE-1–positive lym-
phatic vessels in SCCs of VEGF-A transgenic mice also ex-
pressed VEGFR-2 (Fig. 4 C–E). which indicated that they
were responsive to VEGF-A stimulation. All LYVE-1–posi-
tive tumor-associated vessels also expressed the lymphatic-
specific transcription factor Prox1 (Fig. 4 F), which con-
firmed their lymphatic identity. GFP-expressing SCC cells
in VEGF-A transgenic mice sometimes were detected at-
tached to LYVE-1–positive lymphatics (Fig. 4 G).
We also investigated the mechanisms by which VEGF-A
induces tumor lymphangiogenesis. To assess possible direct ef-
fects on lymphatic endothelial cell (LEC) proliferation and mi-
gration via activation of VEGFR-2 that is expressed by LECs,
cultured human LECs were treated with VEGF-A165 in the
presence or absence of blocking antibodies against VEGFR-2
or VEGFR-3. VEGF-A promoted LEC proliferation by 2.3-
fold (Fig. 4 H). VEGF-A–induced proliferation was inhibited
significantly by blockade of VEGFR-2 (P 
 
 
 
 0.0011), but not
by blockade of VEGFR-3 (Fig. 4 H). Similarly, VEGF-A–
induced LEC migration was inhibited strongly by blockade of
VEGFR-2 (P 
 
 
 
 0.0047), but not of VEGFR-3 (Fig. 4 I).
These results suggest that VEGF-A may be able to stimulate
lymphangiogenesis directly via VEGFR-2.
It is possible that the tumor-associated lymphangiogenesis
that was observed in VEGF-A transgenic mice also could be
mediated, in part, by up-regulation of the known lymphan-
giogenesis factors VEGF-C or VEGF-D. SCC of VEGF-A
transgenic mice, as well as the overlying epidermis, expressed
high levels of VEGF-A mRNA (Fig. 5 C, E), as evaluated by
in situ hybridization. In several tumors and in their overlying
epidermis, weak to moderate expression of VEGF-C mRNA
also was observed (Fig. 5 D, F). VEGF-C–expressing mac-
rophages were observed only occasionally; this indicated that
epidermal keratinocytes and tumor cells are the major source
of VEGF-C production during skin carcinogenesis.
Figure 4. Formation of tumor-associated lymphatic vessels in 
VEGF-A transgenic mice. (A and B) Double immunofluorescence stains 
for CD31 (green) and LYVE-1 (red) reveal initial invasion of angiogenic 
blood vessels (green; arrowheads), but not of lymphatic vessels (red) into 
benign papillomas (A), whereas intratumoral blood vessels often are accompa-
nied by newly formed lymphatic vessels (arrows) in primary cutaneous 
SCC (B) of VEGF-A transgenic mice. (C–E) Intratumoral LYVE-1–positive 
lymphatic vessels (D; red) in SCC express VEGFR-2 (C; green; E   merged 
image; orange/yellow). Green vessels in panel E are LYVE-1-negative blood 
vessels. (F) All tumor-associated LYVE-1–positive vessels (red) also express 
the lymphatic-specific transcription factor Prox1 (green). (G) GFP-expressing 
SCC cells (arrowheads) were found attached to LYVE-1–positive lymphatic 
vessels (red; asterisks). Nuclei are labeled blue (Hoechst stain). Scale bars   
200  m (A and B); 100  m (C–F); 50  m (G). (H) VEGF-A induced LEC
proliferation is inhibited significantly by antibody blockade of VEGFR-2, 
but not of VEGFR-3. (I) Blockade of VEGFR-2, but not of VEGFR-3, inhibits 
VEGF-A–induced LEC migration. Data are expressed as mean   SD (n   5 
per group) and are representative for three independent experiments. 
**P   0.01; ***P   0.001. 
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Quantitative RT-PCR of RNA isolated from skin and
tumor lysates revealed that VEGF-C mRNA expression lev-
els were significantly higher in SCCs of VEGF-A transgenic
mice, compared with their normal skin (P 
 
 
 
 0.015), and that
VEGF-C expression levels were higher in SCCs of VEGF-A
transgenic mice than of the SCCs that developed in wild-
type mice (P 
 
 
 
 0.0002; Fig. 5 H). These results were con-
firmed by immunoprecipitation of SCC lysates, which re-
vealed increased levels of the 58-kD VEGF-C propeptide in
SCCs of VEGF-A transgenic mice (Fig. 5 I). No major dif-
ferences were observed in the proteolytic processing of
VEGF-C protein between wild-type and VEGF-A transgenic
tumors, however (Fig. 5 I). Little or no expression of VEGF-D
mRNA was observed in all tissues by in situ hybridization,
and no major differences of VEGF-D mRNA expression lev-
els between the two genotypes were detected by real-time
RT-PCR (data not depicted). ELISA analysis of tumor ly-
sates confirmed that VEGF-A protein levels were higher in
SCCs of VEGF-A transgenic mice (918.8 
 
 
 
 108.2 pg/mg)
than in wild-type mice (503.9 
 
 
 
 74.1 pg/mg; P 
 
 
 
 0.01; Fig.
5 G); this indicated that tumor-released VEGF-A might pro-
mote expression of VEGF-C, but not of VEGF-D.
 
Increased metastasis to the lymph nodes of VEGF-A 
transgenic mice
 
We next investigated whether the increased levels of tumor
lymphangiogenesis that were observed in the SCCs of VEGF-A
transgenic mice were associated with increases in tumor
metastasis to regional (sentinel) lymph nodes. In situ hybrid-
ization studies confirmed that all metastatic tumors that were
found in VEGF-A transgenic mice maintained high levels of
VEGF-A mRNA expression (data not depicted). As assessed
by fluorescence microscopy, GFP-expressing cells were found
in the sentinel lymph nodes of 100% of SCC-bearing VEGF-A
transgenic mice, but only in the sentinel lymph nodes of
53.8% of SCC-bearing wild-type mice. Flow cytometry anal-
ysis of primary SCC and of sentinel lymph nodes at 8 wk after
the first diagnosis of SCC revealed that 5.9 
 
 
 
 2.1% of all
sorted lymph node cells that were isolated from SCC-bearing
wild-type mice were GFP-positive/CD45-negative metastatic
tumor cells (Fig. 6 C, D), compared with 51.54 
 
 
 
 7.45% for
the primary SCC (Fig. 6 A, B). In contrast, VEGF-A trans-
genic mice demonstrated a significant increase in the percent-
age of GFP-expressing tumor cells within sentinel lymph
nodes (44.61 
 
 
 
 4.32%; P 
 
 
 
 0.0001; Fig. 6 C, D), whereas the
percentage of GFP-positive cells within primary SCC (55.93 
 
 
 
2.44%; Fig. 6 A, B) was comparable to the findings in wild-
type mice. Nontransgenic mice did not show detectable GFP
expression in primary lesions or in lymph nodes (Fig. 6 A, C).
 
Figure 5
 
.
 
Expression of VEGF-A and VEGF-C by SCC of VEGF-A 
transgenic mice.
 
 (A) Representative histologic image (hematoxylin-eosin 
stain) of an SCC from a wild-type mouse shows nests of tumor cells sur-
rounded by compact stroma that contain small vessels. (B) SCC observed 
in VEGF-A transgenic mice were characterized by tissue edema and vessel 
enlargement. Scale bars 
 
 
 
 200 
 
 
 
m (A and B). (C–F) In situ hybridization 
for VEGF-A and VEGF-C mRNA expression in SCC of VEGF-A transgenic 
mice. Normal epidermal keratinocytes of the overlying epidermis (C) and 
SCC tumor cells (E) express high levels of VEGF-A mRNA, whereas stromal 
cells show little or no expression. Occasionally, low levels of focal VEGF-C 
expression were observed in the overlying epidermis (D) and in SCC cells 
(F). Scale bars 
 
 
 
 50 
 
 
 
m (C–F). (G) ELISA analysis of VEGF-A expression in 
skin and tumor lysates (n 
 
 
 
 5 per group) revealed significantly increased 
levels of VEGF-A protein in SCC of both genotypes, as compared with 
normal skin. VEGF-A levels were higher in VEGF-A transgenic mice than in 
wild-type mice. (H) Quantitative real-time TaqMan RT-PCR demonstrated 
increased levels of VEGF-C mRNA expression in the skin and in SCC of 
VEGF-A transgenic mice compared with wild-type mice. VEGF-C expression 
was increased significantly in SCC of VEGF-A transgenic mice, as com-
pared with normal skin. *P 
 
 
 
 0.05; **P 
 
 
 
 0.01; ***P 
 
 
 
 0.001. (I) Immuno-
precipitation of SCC lysates reveals increased levels of the 58-kD VEGF-C 
propeptide in VEGF-A transgenic tumors, as compared with wild-type tu-
mors. No major differences in the proteolytic processing of VEGF-C pro-
tein were found between the two genotypes. Results are representative 
for five independent experiments. 
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Importantly, a greater number of distant lymph nodes
contained SCC metastases in VEGF-A transgenic mice
(57.1% of all SCC-bearing VEGF-A transgenic mice; P 
 
 
 
0.028), compared with wild-type mice with SCC (15.4%).
The percentage of mice with sentinel lymph node metastasis
that also developed distant lymph node metastasis was two-
fold greater in VEGF-A transgenic mice (57.1%) than in
wild-type mice (28.5%). Moreover, the incidence of lung
metastases was significantly higher in VEGF-A transgenic
mice (64.3%; P 
 
 
 
 0.035) than in wild-type mice (23.1%). No
lung metastases were found in mice without lymph node me-
tastasis. Together, these results reveal that VEGF-A not only
induces tumor lymphangiogenesis, but also promotes tumor
metastasis to regional and distal lymph nodes and organs.
 
VEGF-A promotes lymphangiogenesis within sentinel 
lymph nodes
 
Immunofluorescence analysis of the lymph nodes of nontu-
mor-bearing mice revealed comparable numbers of CD31-
positive postcapillary high endothelial venules and LYVE-1–
positive sinusoids in wild-type and transgenic genotypes
(Fig. 7 A, B). Importantly, however, increased numbers of
blood vessels and of LYVE-1–positive lymphatic vessels were
found in the metastasis-containing lymph nodes of VEGF-A
transgenic mice (Fig. 7 F, H), as compared with wild-type
mice (Fig. 7 E, G). The cells of the tumor-associated LYVE-
Figure 6. Increased metastasis to the sentinel lymph nodes in 
VEGF-A transgenic mice. (A and C) Representative flow cytometry anal-
ysis of GFP-expressing, CD45-negative cells in primary SCC and in sentinel 
lymph node (LN). Whereas no GFP-positive cells were found in nontransgenic 
control mice at 8 wk after the first detection of cutaneous SCC, 53.5% of 
all SCC-derived cells in K14/GFP transgenic mice and 67.9% in K14/GFP/
VEGF-A transgenic mice were GFP-positive (A). In contrast, the percentage 
of GFP-expressing tumor cells was significantly higher in metastases to 
the sentinel lymph nodes of K14/GFP/VEGF-A transgenic mice (50.2%) 
than of K14/GFP transgenic mice (4.9%; C). (B and D) Statistical analysis 
revealed a significant increase of GFP-positive tumor cells in the sentinel 
lymph node metastases of VEGF-A/GFP double transgenic mice, compared 
with GFP transgenic mice (D), whereas no significant differences were 
found in the primary lesions (B). Data are expressed as mean   SEM 
(n   5 per group). ***P   0.001.
Figure 7. Increased lymph node lymphangiogenesis in VEGF-A 
transgenic mice. Double immunofluorescence stains of lymph nodes of 
nontumor-bearing mice demonstrate a comparable pattern of CD31-positive 
postcapillary high endothelial venules (green) and LYVE-1–positive sinusoids 
(red) in wild-type (WT) mice (A) and in VEGF-A transgenic (VEGF-TG) mice 
(B). Nonmetastatic sentinel lymph nodes of SCC-bearing VEGF-A transgenic 
mice have increased numbers of enlarged LYVE-1–positive sinusoids (red; 
D), as compared with wild-type mice (C). Increased numbers of enlarged 
LYVE-1-positive lymphatic vessels (red) and of CD31-positive blood vessels 
(green) were found in the metastatic sentinel lymph nodes of VEGF-A 
transgenic mice (F), as compared with wild-type mice (E). (G and H) Higher 
magnification of panels E and F, respectively. The tumor-associated LYVE-1–
positive vessels (red) in VEGF-A transgenic mice had high levels of BrdU 
staining in lymphatic endothelial cells (I; green), indicating active lymphatic 
proliferation (arrowheads) within the sentinel lymph node. These cells also 
expressed Prox1 (J; green). Blood vessels (J; asterisks) do not express 
LYVE-1 or Prox1. ‘Met’ indicates a metastasizing cutaneous SCC. Nuclei 
are labeled blue (Hoechst stain). Scale bars   100  m (A–D and I); 200  m 
(E–H); 50  m (J). 
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1–positive vessels in VEGF-A transgenic mice were under-
going high levels of proliferation, as revealed by 5-bromo-
2
 
 
 
-deoxyuridine (BrdU) staining (Fig. 7 I). All LYVE-1–
positive vessels in VEGF-A transgenic mice also expressed
Prox1, which confirmed their lymphatic identity (Fig. 7 J).
These results demonstrate that overexpression of VEGF-A in
the skin promotes tumor-associated active lymphangiogene-
sis in the metastatic lymph nodes, and that the tumor-associ-
ated lymphatic vessels maintain their lymphatic phenotype.
We next analyzed the nonmetastasis–containing lymph
nodes of tumor-bearing mice of both genotypes. Surpris-
ingly, we found increased numbers of enlarged LYVE-1–
positive sinusoidal vessels in nonmetastasis–containing drain-
ing lymph nodes of tumor-bearing VEGF-A transgenic mice
(Fig. 7 D), as compared with tumor-bearing wild-type mice
(Fig. 7 C). In contrast, no major difference was found in the
number of CD31-positive vessels (Fig. 7 C, D). These in-
triguing findings reveal that VEGF-A, which is secreted by
primary skin tumors, induces lymphangiogenesis within the
draining lymph nodes, even before the tumor has metasta-
sized to these tissues; this may facilitate future metastatic tu-
mor spread within the lymphatic system.
 
DISCUSSION
 
Our study identifies VEGF-A as a novel tumor lymphan-
giogenesis factor. Consistent transgenic overexpression of
mouse VEGF-A164, specifically in the skin, resulted in en-
hanced numbers of enlarged, actively proliferating, tumor-
associated lymphatic vessels during multi-step skin carcino-
genesis. Previously, VEGF-A was considered to be only a
(blood vascular) tumor angiogenesis factor, signaling through
VEGFR-2 and possibly VEGFR-1, which are expressed on
tumor-associated blood vessels (2, 28, 29). Indeed, a large
number of studies showed that overexpression of VEGF-A
in tumor xenotransplants promotes tumor angiogenesis (30),
and that systemic inhibition of VEGF-A, VEGFR-1, or
VEGFR-2 inhibits tumor growth and angiogenesis in exper-
imental mouse tumor models and in human cancers (30–32).
Only one of these studies (4), however, investigated the
effects of VEGF-A on tumor-associated lymphatic vessel for-
mation—largely because of the absence of specific markers
for lymphatic vessels. We have used the lymphatic endothe-
lium-specific hyaluronan receptor, LYVE-1 (25, 33), as a
marker to detect and quantify tumor-associated lymphatic
vessels. LYVE-1 also is expressed by some nonlymphatic en-
dothelial cells, such as those of liver sinusoids (34) and of
embryonic veins (35); therefore, to increase specificity we
also monitored expression of the transcription factor Prox1,
which is expressed specifically by lymphatic, but not by
blood, vessels (35). Using these two markers, we were able
to quantify carefully lymphatic vessels that are associated
with tumors and metastases.
The role of active lymphangiogenesis in tumor growth
has been questioned, as it has been proposed that tumor-
associated lymphatic vessels might represent preexisting lym-
phatics within or surrounding rapidly-invading tumor xe-
notransplants (36). Through analysis of BrdU and LYVE-1
levels, however, our study reveals that active proliferation of
lymphatic endothelial cells occurs within and surrounding
the slowly growing, orthotopic cutaneous SCC, and that
overexpression of VEGF-A increases proliferation of cells in
the lymphatic vessels. Together, these results confirm that
tumors can induce the growth of tumor-associated lym-
phatic vessels actively, and that VEGF-A promotes tumor
lymphangiogenesis. In contrast, a previous study of VEGF-
A–transfected human 293 cell xenotransplants did not detect
promotion of tumor lymphangiogenesis (4). These findings
might be due to different levels of VEGF-A expression, the
significantly shorter observation period, and a possible dif-
ferent genetic lymphangiogenic disposition between the
different mouse strains that were used. The multi-step skin
carcinogenesis model that was used in our study—with au-
tochtonous tumors developing slowly over a period of sev-
eral months—likely resembles the pathogenesis of human tu-
mors more closely than the widely used xenotransplant
models of human cancer cell lines in immunodeficient mice.
There also is controversy over whether VEGF-A can in-
duce lymphangiogenesis, and, if so, whether VEGF-A in-
duces lymphatic vessel growth directly or via up-regulation
of the thus far only known direct lymphangiogenesis factors,
VEGF-C and VEGF-D. VEGF-C and -D also were shown
to induce tumor lymphangiogenesis potently and to be up-
regulated in a large number of metastatic human cancers
(3–6, 8, 9, 37). Whereas injection of adenoviral human
VEGF-A165 into murine skin did not result in increased
sprouting of lymphatic vessels, although lymphatic enlarge-
ment was observed (18), injection of the ears of mice with
an adenoviral vector that expressed mouse VEGF-A164 ac-
tively promoted new lymphatic vessel formation and prolif-
eration of lymphatic vessel cells. This occurred without any
detectable up-regulation of VEGF-C or VEGF-D (16).
We also showed previously that overexpression of mu-
rine VEGF-A164 in the skin promoted lymphatic vessel
formation during cutaneous tissue repair (13) and during
chronic skin inflammation (19), without detectable up-regu-
lation of VEGF-C or VEGF-D. Moreover, cultured dermal
LECs express VEGFR-2, and we found that treatment of
LECs with human VEGF-A165 potently promoted LEC
proliferation and migration that was inhibited by blockade of
VEGFR-2, but not VEGFR-3. Together with our findings
that tumor-associated lymphatic vessels in VEGF-A trans-
genic mice expressed VEGFR-2 during skin carcinogenesis,
it is conceivable that VEGF-A directly induces the formation
of lymphatic vessels.
In this study, we observed that levels of VEGF-C (but
not of VEGF-D) mRNA and protein expression were in-
creased in VEGF-A–overexpressing tumors; this is in agree-
ment with the finding that VEGF-A treatment up-regulates
VEGF-C expression in cultured endothelial cells (38); how-
ever, the proteolytic processing of VEGF-C protein was not 
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altered in VEGF-A–overexpressing tumors. So the relative
importance of different mechanisms by which VEGF-A pro-
motes tumor lymphangiogenesis—whether via direct or in-
direct up-regulation of VEGF-C, or other factors, such as fi-
broblast growth factors or angiopoietin—remains to be
elucidated. Once they become available, studies with re-
agents that block VEGFR-3 signaling in mice or that specif-
ically neutralize VEGF-C might answer these questions.
Our findings that chronic transgenic overexpression of
VEGF-A in the skin promoted skin carcinogenesis and tu-
mor angiogenesis are in agreement with a large number of
studies in tumor xenotransplants (30) and with a previous
study in transgenic mice with skin-specific overexpression of
the mouse VEGF120 isoform (39). It is remarkable that de-
spite the fact that VEGF-A transgenic mice developed more
benign papillomas and more malignant SCCs, the ratio of
malignant conversion of large papillomas into SCC was
comparable in VEGF-A transgenic mice and in wild-type
mice. These findings are in agreement with previous findings
in thrombospondin-2–deficient mice (23), and they indicate
that increased levels of VEGF-A did not result in major ad-
ditional genetic events. Instead, the increased number of
SCCs in VEGF-A transgenic mice most likely reflects the
acceleration in the early stages of skin carcinogenesis, be-
cause comparable latency periods between papilloma and
SCC formation were observed in both genotypes.
Importantly, we found that tumor metastasis to regional
(sentinel) lymph nodes occurred more frequently in VEGF-A
transgenic mice than in wild-type mice; this indicated that
VEGF-A–induced tumor lymphangiogenesis of primary cu-
taneous SCC promoted metastasis to these tissues. In studies
in human cutaneous melanomas, the degree of tumor-associ-
ated lymphangiogenesis was correlated with future lymph
node metastasis and with reduced overall survival (6), and in-
dicated the clinical relevance of tumor lymphangiogenesis in
human cancer. The establishment of the K14/GFP trans-
genic model has allowed us to quantify the incidence of
SCC metastasis to sentinel and distant lymph nodes in re-
sponse to increased levels of lymphangiogenesis. This model
also might be used to study other factors that contribute to
multi-step skin carcinogenesis and metastasis.
One of the most important and novel findings of our study
was that VEGF-A–overexpressing SCC cells maintained their
lymphangiogenic activity after metastasizing to sentinel lymph
nodes; this resulted in increased numbers of proliferating
LYVE-1– and Prox1-positive lymphatic vessels within lymph
nodes. These results indicate that VEGF-A not only promotes
primary tumor lymphangiogenesis, but also induces lymph
node lymphangiogenesis. It is tempting to speculate that this
newly identified phenomenon of “lymph node lymphangio-
genesis” might facilitate further metastatic tumor spread through-
out the lymphatic system, because the percentage of mice with
sentinel lymph node metastasis that also developed distant
lymph node metastasis was twofold greater in VEGF-A trans-
genic mice than in wild-type mice.
Therefore, VEGF-A might represent a novel target for
treating patients who have advanced forms of SCC or other
cancers, as well as to prevent metastasis to sentinel lymph
nodes. Systemic inhibition of VEGF-A by a blocking anti-
body (bevacizumab) recently was shown to retard tumor
progression in patients who had metastatic colorectal or renal
cancer. Our present study suggests that systemic anti–VEGF-A
treatment also might prevent the systemic spread of an
early-stage malignancy by inhibiting tumor lymphangiogen-
esis and/or lymph node lymphangiogenesis. Future studies
that use long-term neutralization of VEGF-A during multi-
step carcinogenesis in mice or in novel models of lymph
node metastasis are needed to determine whether VEGF-A
blockade might inhibit the further metastatic spread of al-
ready existing, potentially dormant micrometastases within
sentinel (or distant) lymph nodes.
Perhaps the most surprising finding of our study was that
even before metastasizing to the lymph nodes, VEGF-A–
overexpressing primary tumors induced sentinel lymph node
lymphangiogenesis. This suggests that primary tumors might
begin preparing their future metastatic site by producing lymph-
angiogenic factors that mediate their efficient transport to sen-
tinel lymph nodes. This concept is an important new twist to
the previously proposed “seed-and-soil” hypothesis for the
preferential organ metastasis pattern of distinct human tumors.
The induction of lymphangiogenesis within the premet-
astatic lymph nodes was much more dramatic than the in-
duction of angiogenesis. This suggests that the fluid which is
drained from the primary tumors into the sentinel lymph
node promotes their further metastatic spread from sentinel
lymph nodes. Initiation of antilymphangiogenic (or anti–
VEGF-A) therapy during the presurgery period, immedi-
ately after the diagnosis of cancer, might reduce the future
risk for metastasis of SCC or other tumor types to lymph
nodes in patients.
 
MATERIALS AND METHODS
 
Generation of K14/GFP and of K14/GFP/VEGF-A transgenic
mice.
 
A 787-bp fragment that encodes enhanced GFP cDNA was ob-
tained by PCR amplification from a pEGFP vector template (BD Bio-
sciences) and was cloned into the BamHI site of a K14 promoter/pGEM-
3Z transgene expression cassette ([24]; provided by E. Fuchs, Rockefeller
University, New York,
 
 
 
NY). A 5.4-kb KpnI–HindIII fragment (Fig. 1 A)
was used to generate transgenic mice on the FVB genetic background as de-
scribed (20). Transgenic founders were detected by Southern blot analysis.
For rapid identification, GFP expression was analyzed in the tails of 12-day-
old mice, using a Nikon TE-300 fluorescence microscope. Three indepen-
dent homozygous transgenic lines were established. After confirmation of
specific GFP expression in sites that previously were shown to express K14
(24), the transgenic line with the highest level of GFP expression was
crossed with previously established and characterized heterozygous K14/
VEGF-A transgenic mice (20), to establish K14/GFP and K14/GFP/
VEGF-A transgenic mice. All animal studies were approved by the Massa-
chusetts General Hospital Subcommittee on Research Animal Care.
 
Chemical skin carcinogenesis regimen.
 
For tumor initiation, 50 
 
 
 
g of
DMBA (Sigma-Aldrich) was applied topically to the shaved back skin of
8-wk-old female K14/GFP/VEGF-A transgenic mice (n 
 
 
 
 34), K14/GFP 
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transgenic mice (n 
 
 
 
 31), and FVB wild-type mice (n 
 
 
 
 29), followed by
weekly topical application of 5 
 
 
 
g of the tumor promoter PMA (Sigma-
Aldrich) over 20 wk as described (22, 23). Raised lesions of a minimum di-
ameter of 1 mm that had been present for at least 1 wk were recorded as tu-
mors. Mice were killed after 35 wk, or at 8 wk after the first diagnosis of
SCC. The ratio of malignant conversion was calculated for each group of
mice as the total number of SCC divided by the number of large papillo-
mas, expressed as a percentage. The two-sided unpaired Student’s 
 
t
 
 test was
used to analyze differences in the number of tumors per mouse between
VEGF-A transgenic and wild-type mice. Regional and distal lymph node
involvement was evaluated clinically and by fluorescence microscopy of
100-
 
 
 
m step sections. Lung metastases were evaluated on 100-
 
 m step sec-
tions. Metastasis data were analyzed by the Mann-Whitney test.
Immunofluorescence, in situ hybridization, ELISA, and immuno-
precipitation. Tumors or skin samples were fixed for 2 h in 4% parafor-
maldehyde and were embedded in paraffin or in optimal cutting temperature
compound (Sakura Finetek) and snap-frozen, or were freshly frozen. At au-
topsy, all axillary and inguinal lymph nodes of SCC-bearing mice were ex-
amined for the presence of metastases. The presence of metastases was con-
firmed further by fluorescence microscopic analysis of GFP expression in five
100- m-thick serial sections for each lymph node. Immunostains were per-
formed on 6- m paraffin sections or cryostat sections as described previously
(23), using a rat mAb against CD31 (BD Biosciences), a goat polyclonal anti-
body to mouse VEGFR-2/Flk-1 (R&D Systems), a rat monoclonal and a
rabbit polyclonal antibody to mouse LYVE-1 (a gift from D. Jackson, Uni-
versity of Oxford, Oxford, England; reference 25), a rabbit anti-Prox1 anti-
body (Covance), and corresponding secondary antibodies labeled with Alexa
Fluor 488 or 594 (Molecular Probes). Before most immunostains, frozen sec-
tions were photobleached by exposure to ultraviolet B irradiation. Nuclei
were counterstained with Hoechst bisbenzimide (Molecular Probes). Mice
were injected with BrdU, 50 mg/kg (Sigma-Aldrich) 2 h before sacrifice,
and a FITC-conjugated mouse mAb to BrdU (BD Biosciences) was used for
detection of proliferating cells. In situ hybridization was performed as de-
scribed (20). Antisense and sense single-stranded 35S-labeled RNA probes for
VEGF-A, VEGF-C, and VEGF-D were as described previously (16). Mu-
rine VEGF-A protein levels were quantified by ELISA (Quantikine M;
R&D Systems) of skin or tumor lysates as described (19). Statistical analysis
was performed using the unpaired Student’s t test. SCC lysates (n   5 per
genotype) also were immunoprecipitated using a rabbit anti-VEGF-C anti-
body (Abcam Inc.), followed by SDS-PAGE under reducing conditions and
Western blotting using a goat anti-VEGF-C antibody (R&D Systems).
Computer-assisted morphometric vessel analysis. Representative
LYVE-1 and CD31 double-stained sections, obtained from biopsies of
PMA-treated skin (n   5), small papillomas (1–3 mm in diameter; n   5),
large papillomas ( 3 mm in diameter; n   6), and SCC (n   6) were ana-
lyzed for each genotype, using a Nikon E-600 microscope. Images were
captured with a Spot digital camera (Diagnostic Instruments), and computer-
assisted morphometric analyses of blood vessels and lymphatic vessels were
performed as described (22), using the IP-LAB software (Scanalytics). Statis-
tical analyses were performed using the two-sided, unpaired Student’s t test.
Flow cytometry analysis. Tissue samples of SCC and of sentinel lymph
nodes were minced gently in PBS, followed by incubation with 0.25%
trypsin (Invitrogen) for 10 min at 37 C. Single-cell suspensions were pre-
pared as described (26), and were passed through 40- m pore size cell
strainers (BD Biosciences), washed in PBS, and stained with a PE-labeled
mouse anti-CD45 antibody (BD Biosciences) and with propidium iodide.
The stained cells ( 10,000 cells per sample) were subjected to flow cytom-
etry with a FACScan and a FACSCalibur instrument (BD Biosciences).
GFP expression was detected under FITC settings (26).
Quantitative real-time RT-PCR. Total RNA was isolated from mouse
skin or SCC by using Trizol reagent (Sigma-Aldrich). Taqman-based real-
time RT-PCR reactions for murine VEGF-C, VEGF-D, and GAPDH
were performed as described (19). GAPDH transcripts were measured si-
multaneously in all reactions as internal controls. Total RNA was treated
with RNase-free RNA qualified–DNase (Promega) before analysis, and 50
ng of total RNA was used for each reaction. Data were normalized based
on the expression levels of GAPDH.
Cell proliferation and migration assays. Human dermal LECs were
isolated from neonatal foreskins as described (12). For proliferation assays,
cells (2   103) were seeded onto fibronectin-coated 96-well plates and were
pretreated (n   5 per treatment group) with 5  g/ml of anti–human
VEGFR-2 mAb (89106, R&D Systems), anti–human VEGFR-3 mAb
(hF4-3C5, Imclone), or control IgG for 16 h, followed by incubation with
or without recombinant human VEGF-A165 (10 ng/ml; R&D Systems) in
endothelial cell basic medium containing 2% FBS. After 48 h, cells were in-
cubated with 4-methylumbelliferylheptanoate (Sigma-Aldrich) and result-
ing fluorescence—which is correlated to the number of living cells (27)—
was quantified using a Victor2 Fluorometer (PerkinElmer). Haptotactic
LEC migration was studied as described (13). Cells were seeded in serum-
free endothelial cell basic medium containing 0.2% delipidized BSA into
the upper chambers of FluoroBlok inserts (Falcon) in the presence of anti–
human VEGFR-2 mAb (10  g/ml), anti–human VEGFR-3 mAb (5  g/
ml), or corresponding control IgG, and were incubated for 3 h at 37 C in
the presence or absence of VEGF-A165 (10 ng/ml). Cells on the underside
of inserts were stained with Hoechst 33342 (Molecular Probes), and the
number of migrated cells was determined by computer-assisted image anal-
ysis of three random 20  fields per well. Three independent experiments
were performed for each assay. Statistical analyses were performed by using
the unpaired Student’s t test.
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